Prostatic Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
Furthermore, we showed in preclinical models that BRG1 antagonist selectively inhibited the progression of PTEN-deficient prostate tumors.
|
30496141 |
2019 |
Prostatic Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
PTEN loss stimulates prostate tumor progression by sustaining AKT activation.Nowak et al.(2019.<i>J.
|
31145683 |
2019 |
Prostatic Neoplasms
|
0.600 |
Biomarker
|
group |
CTD_human |
Cribriform and intraductal prostate cancer are associated with increased genomic instability and distinct genomic alterations.
|
29295717 |
2018 |
Prostatic Neoplasms
|
0.600 |
Biomarker
|
group |
CTD_human |
The long tail of oncogenic drivers in prostate cancer.
|
29610475 |
2018 |
Prostatic Neoplasms
|
0.600 |
Biomarker
|
group |
CTD_human |
An aberrant SREBP-dependent lipogenic program promotes metastatic prostate cancer.
|
29335545 |
2018 |
Prostatic Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
High intracellular ROS levels selectively sensitize cells displaying hyperactive Akt to ROS-induced cell death enabling a therapeutic strategy combining a ROS inducer and rapamycin in PTEN-deficient prostate tumors in mouse models.
|
29687779 |
2018 |
Prostatic Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
Furthermore, ADT combined with vaccination, specifically a DNA vaccine encoding the ligand-binding domain of the AR, led to improved antitumor responses as measured by tumor volumes and delays in the emergence of castrate-resistant prostate tumors in two murine prostate cancer models (Myc-CaP and prostate-specific PTEN-deficient mice).
|
29051161 |
2017 |
Prostatic Neoplasms
|
0.600 |
Biomarker
|
group |
CTD_human |
A single-copy Sleeping Beauty transposon mutagenesis screen identifies new PTEN-cooperating tumor suppressor genes.
|
28319090 |
2017 |
Prostatic Neoplasms
|
0.600 |
AlteredExpression
|
group |
BEFREE |
Here, we provide evidence that PTEN loss in prostate tumours upregulates the expression of ADAM17, thereby activating NOTCH signalling.
|
27941799 |
2016 |
Prostatic Neoplasms
|
0.600 |
GeneticVariation
|
group |
BEFREE |
We studied the sensitivity and specificity of PTEN immunohistochemistry relative to four-color fluorescence in situ hybridization (FISH) for detection of PTEN gene deletion in a multi-institutional cohort of 731 primary prostate tumors.
|
27174589 |
2016 |
Prostatic Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
We have quantitatively analyzed the mRNA levels of TMPRSS2-ERG, ERG, PTEN, and AR (n = 83), as well as ERG immunostaining (n = 78) in a series of prostate tumors.
|
25939480 |
2015 |
Prostatic Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
Met was amplified in 67% of prostate tumors from Pten p53 prostate conditional null mice and in approximately 30% of metastatic human prostate cancer specimens, often in association with loss of PTEN and TP53.
|
25381262 |
2015 |
Prostatic Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
PTEN loss in Gleason score 6 biopsies identifies a subset of prostate tumors at increased risk of upgrading at radical prostatectomy.
|
24993522 |
2015 |
Prostatic Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
KLF5 loss enhances tumor angiogenesis by attenuating PI3K/AKT signaling and subsequent accumulation of HIF1α in PTEN deficient prostate tumors.
|
25896712 |
2015 |
Prostatic Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
This report describes a novel mouse model that overexpresses ERG and lacks PTEN with the majority of mice developing prostate tumors by 6 mo.
|
25007053 |
2014 |
Prostatic Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
Here, we show that AKT2 is exclusively required for PTEN-deficient prostate tumor spheroid maintenance, whereas AKT1 is dispensable. shRNA silencing of AKT2 but not AKT1 promotes regression of prostate cancer xenografts.
|
24838891 |
2014 |
Prostatic Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
Here we show that at the onset of senescence, PTEN null prostate tumours in mice are massively infiltrated by a population of CD11b(+)Gr-1(+) myeloid cells that protect a fraction of proliferating tumour cells from senescence, thus sustaining tumour growth.
|
25156255 |
2014 |
Prostatic Neoplasms
|
0.600 |
Biomarker
|
group |
CTD_human |
Dietary resveratrol prevents development of high-grade prostatic intraepithelial neoplastic lesions: involvement of SIRT1/S6K axis.
|
23248098 |
2013 |
Prostatic Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
Behavioral stress inhibited apoptosis and delayed prostate tumor involution both in phosphatase and tensin homolog-deficient (PTEN-deficient) prostate cancer xenografts treated with PI3K inhibitor and in prostate tumors of mice with prostate-restricted expression of c-MYC (Hi-Myc mice) subjected to androgen ablation therapy with bicalutamide.
|
23348742 |
2013 |
Prostatic Neoplasms
|
0.600 |
GeneticVariation
|
group |
BEFREE |
Using the conditional PTEN deletion mouse model, we previously reported that survivin levels increase with prostate tumor growth.
|
23936028 |
2013 |
Prostatic Neoplasms
|
0.600 |
Biomarker
|
group |
CTD_human |
Dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine-induced prostate carcinogenesis in CYP1A-humanized mice.
|
22581815 |
2012 |
Prostatic Neoplasms
|
0.600 |
AlteredExpression
|
group |
BEFREE |
Immunofluorescence data and western blot analyses determined that a lentivirus containing a 5'UTR derived from FGF-2 is the best candidate for directing selective gene expression in the prostate tumors of PTEN(-/-) mice in vivo.
|
21921943 |
2012 |
Prostatic Neoplasms
|
0.600 |
Biomarker
|
group |
CTD_human |
Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer.
|
22610119 |
2012 |
Prostatic Neoplasms
|
0.600 |
AlteredExpression
|
group |
BEFREE |
IGF-IR expression positively correlates with PTEN and inversely correlates with NRP2 in prostate tumors.
|
22777769 |
2012 |
Prostatic Neoplasms
|
0.600 |
Biomarker
|
group |
CTD_human |
Resveratrol and prostate cancer: promising role for microRNAs.
|
21714127 |
2011 |